Press Releases
Interim Results for the Six Months Ended 30 June 2015
Click here to download the full 2015 interim results statement – Clinical programs on track – – Cat allergy phase III to report H1 2016; recruitment for grass allergy phase III to start H1 2016...
View detailsNotice of Interim Results
Oxford, UK – 20 July 2015: Circassia Pharmaceuticals plc (“Circassia” or “the Company”) (LSE: CIR), a specialty biopharmaceutical company focused on allergy and asthma, will announce its interim results for the six months ended 30...
View detailsCircassia’s Extended Offer Period for Aerocrine has Increased Acceptances to 97.2 Percent
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN,...
View detailsCompletion of Acquisition of Prosonix Limited
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN,...
View detailsResults of the Placing and Open Offer
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN,...
View detailsPlacing and Open Offer of New Ordinary Shares
Click here to download the full Placing and Open Offer announcement THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY...
View detailsProposed Acquisitions of Aerocrine AB and Prosonix Limited Creating a World-Class Allergy and Asthma Specialty Pharma Business
Click here to download the full Proposed Acquisitions announcement NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN...
View detailsPreliminary Results for the Year Ended 31 December 2014
Click here to download the full 2014 preliminary results statement – Strong clinical progress; Cat-SPIRE phase III study fully recruited – – Robust financial position; fully-funded to bring Cat-SPIRE to market – – Commercialisation preparations...
View detailsCircassia Appoints Lota S Zoth as Non-Executive Director
Click here to download full press release Oxford, UK – 9 February 2015: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty biopharmaceutical company focused on allergy, today announces the appointment of Lota...
View detailsNotice of Preliminary Results
Oxford, UK – 27 January 2015: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty biopharmaceutical company focused on allergy, will announce its preliminary results for the year ended 31 December 2014 on...
View details